Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Preoperative weight changes
研究概览
简要总结
Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.
详细描述
Objective
Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery.
Methods:
It is a single center, quasi-experimental prospective before-and-after study. All patients were assigned the same pharmacological treatment with liraglutide, initiating dosing with 0.6 mg per day escalating 0.6 mg every week up to 3.0 mg. The treatment dose was delivered once daily via subcutaneous injection for 3 months (12 weeks). Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance (BIA) final result at week 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with BMI greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the Bariatric and Metabolic Surgery Unit of the Civil Hospital of Guadalajara "Dr. Juan I. Menchaca
排除标准
- •Patients under 18 years of age or over 65 years of age.
- •Pregnant patients.
- •Patients who do not agree to give their consent and take part in the study.
- •Patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones.
- •Patients who decide to abandon the study.
- •Patients who do not follow the instructions or do not adhere to the treatment.
研究组 & 干预措施
Patients with morbid obesity in bariatric surgery preparation protocol
All patients with body mass index >48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss
干预措施: Liraglutide injection (Drug)
结局指标
主要结局
Preoperative weight changes
时间窗: 3 months
Total body weight change during the drug administration
次要结局
未报告次要终点
研究者
Jose Daniel Reyes Blandón
Bariatric Surgery Resident
Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca